Tiptree will “revisit” whether to float Fortegra “at some point”
Tiptree’s chairman has said the New York-based holding company will revisit the question of whether to float Fortegra, after the insurance subsidiary posted a 79.2 percent increase in gross written premiums and premium equivalents in Q2.
If you are a subscriber, please sign back in to read this article
If you are not currently a subscriber please see contact details below